The Latest Breaking News from Alnylam Pharmaceuticals

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:

According to data from Benzinga Pro, during Q1, Alnylam Pharmaceuticals's (NASDAQ:ALNY) reported sales totaled $213.26 million. Despite a 7.01% increase in earnings, the company posted a loss of $240.34 million.

Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

  Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q1 earnings results on Thursday, April 28, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Morgan Stanley downgraded its rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) to Equal-Weight with a price target of $178.00, changing its price target from $210.00 to $178.00. Shares of Alnylam Pharmaceuticals are trading down 4.47% over the last 24 hours, at $159.53 per share.

 

  Alnylam Pharmaceuticals (NASDAQ:ALNY) will host a conference call at 08:30 AM ET on April 28, 2022, to discuss Q1 2022 earnings results.

A Relative Strength Rating upgrade for Alnylam Pharmaceuticals shows improving technical performance. Will it continue?

Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:

Health Canada has approved Moderna Inc's (NASDAQ:MRNA) mRNA COVID-19 vaccine, Spikevax, two-dose series of 50 µg per dose to prevent COVID-19 in children aged six to11 years. The announcement follows the recent authorization of the Company's COVID-19 vaccine in the same age group in both Australia and the European Union. "Health Canada was…

Alnylam Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating